Inscription et Covid safe ticket obligatoires pour y participer. Plus d’informations sur cette page.
“Biomanufacturing: the future starts in Belgium”. Le 21 septembre 2021, les opportunités de la bioproduction belge seront au cœur de l’événement annuel de bio.be/essenscia. Thomas Dermine, secrétaire d’État pour la Relance et les Investissements stratégiques, chargé de la Politique scientifique, sera l’invité d’honneur de cet événement.
Un vent nouveau souffle sur le secteur biotech belge. Les entreprises biotechnologiques passent de plus en plus du ’invented in Belgium’ au ‘made in Belgium’. Lors de l’événement, nous traiterons des questions suivantes : Quel rôle pour les biotechnologies dans le cadre du plan de relance ? Quelle place occupent nos capacités de bioproduction dans la compétition mondiale ? Quelles sont les opportunités en matière de digitalisation et durabilité ? Comment faire de la Belgique un centre d’excellence des ‘factories of the future’ ? Découvrez-le à cette occasion.
L’événement aura lieu en anglais au BluePoint à Bruxelles dans le respect des mesures sanitaires en vigueur
Programme
- 13:15 : Welcome & Registration
- 14:00 : Introduction
Tineke Van hooland, Deputy Secretary General bio.be - Keynote speech
Thomas Dermine, State Secretary for Economic Recovery and Strategic investments in charge of Scientific Policy - Panel debate
Eva Leclercq, Digital Transformation – Univercells
Benoit van den Hove, Head of Listing Belgium and Luxembourg – Euronext
Julien Moindrot, Site Head – Sanofi
Hendrik Waegeman, Head of Business Operations – Bio Base Europe Pilot Plant
Moderated by Frédéric Druck, Secretary General bio.be/essenscia - Company testimonial videos from Johnson & Johnson, GSK and Univercells
- Conclusion
Geoffrey Pot, President board bio.be
Inscription et Covid safe ticket obligatoires pour y participer. Plus d’informations sur cette page.
 |
Thomas Dermine, is a French-speaking Belgian economist and politician who is a member of the Socialist Party.
On 1 October 2020, he was appointed State Secretary for Economic Recovery and Strategic Investment with responsibility for Science Policy, deputy to the Minister for the Economy and Labour in Alexander De Croo’s federal government. Within the federal government, he is responsible for steering the coordination of the Belgian Recovery Plan and ensuring close cooperation between the European Commission and Belgium. In parallel with this mission, Thomas also supervises the Federal Science Policy, including 10 federal scientific establishments and a multitude of competences ranging from Belgian aerospace policy to the management of federal museums and federal research policy. |
 |
Eva Leclercq is digital transformation manager at Univercells and drives digital transformation projects across the 4 affiliates of the Belgian group. After graduating in business engineering from Université de Liège and Université Catholique de Louvain, she joined Accenture as a consultant in digital analytics, and managed innovative projects across R&D, quality, commercial, etc. for several big pharmaceutical groups. |
 |
Julien Moindrot holds a master’s degree in engineering from the Ecole des Arts et Métiers de Paris (ENSAM – Paris, France) and is certified in Environmental Technologies (University of Trondheim, Norway). He has more than 20 years of experience in the pharmaceutical and biotech environment, holding several roles in Project management, Engineering, Business Excellence and Transformation.
Julien has more than 10 years of experience within Sanofi, where he started as Head of Business Excellence & Engineering and evolved to Head of Strategy and Industrial Performance in Geel. In 2016, Julien was appointed Global Transformation Leader, responsible for the operational and performance transformation of 7 sites of the Biologics platform. Since November 2020 Julien leads the bio-manufacturing site of Sanofi in Geel (> 800 employees) as Site Head. |
 |
Geoffrey Pot studied Pharmacy / Industrial Pharmacy and has more than 15 years of experience in the Biotech environment. He followed an International Management Degree at the Vlerick Business School, and has a natural passion for innovation and digital. He has been holding several roles of increasing responsibility in Quality, Operational Excellence, Project management, Manufacturing, and Innovation. As of today, Geoffrey is a Vice President, and is responsible for the Lessines manufacturing plant (>1200 employees) where they produce lifesaving medication. He is also the President of Belgian Biotech Industries (bio.be/essenscia) and chairman in multiple international conferences. |
 |
Benoît is Head of Listing of Euronext Brussels and Luxembourg. He joined Euronext in 2018 after having spent 17 years in a leading Benelux bank where he held different roles in the financial and capital markets and 2 years in a law firm. Benoit holds a Master’s Degree in Law (KULeuven) and an executive Masters in Business Administration (Louvain School of Management |
 |
Hendrik Waegeman obtained a master degree in biochemical engineering at Ghent University (2007) and holds a PhD in Applied Biological Sciences-Chemical Engineering (2011), also obtained at Ghent University. During his doctoral research he metabolically engineered Esherichia coli to improve recombinant protein production. During his post-doctoral research, Hendrik Waegeman was involved in a number of projects that focused on the fermentative production of specialty carbohydrates. He is also a co-founder of the company Inbiose NV, founded in 2013, which develops fermentatively produced specialty carbohydrates such as human milk oligoscaccharides. In 2012 he was guest lecturer at the University of Incheon, South-Korea where he lectured a course on Metabolic Engineering and Modelling of Micro-organisms. Since 2012, he has a position at Bio Base Europe Pilot Plant, a multi-purpose pilot facility in the Port of Ghent in Belgium where he has worked as Head of Business Development and is now Head of Business Operations.
Hendrik is also board director of Inbisoe NV, Bio.be (the cluster of Belgian biotech companies) and Biobased Industries Consortium (BIC, the private partner in the joint undertaking Horizon2020-BBI and the upcoming joint undertaking CBE (Circular Bio-based Europe). |
